Stock Yards Bank & Trust Co. lifted its holdings in shares of  AstraZeneca PLC (NASDAQ:AZN – Get Rating) by 4.1% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor  owned 6,843 shares of the company’s stock after buying an additional 269 shares during the quarter. Stock Yards Bank & Trust Co.’s holdings in AstraZeneca were worth $464,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently bought and sold shares of AZN. Parkside Financial Bank & Trust lifted its position in shares of  AstraZeneca by 4,875.0% during the first quarter. Parkside Financial Bank & Trust now owns 398 shares of the company’s stock worth $26,000 after acquiring an additional 390 shares in the last quarter.  Hazlett Burt & Watson Inc. grew its position in shares of  AstraZeneca by 129.5% in the third quarter. Hazlett Burt & Watson Inc. now owns 514 shares of the company’s stock valued at $28,000 after purchasing an additional 290 shares in the last quarter.  Fairfield Bush & CO. bought a new stake in shares of  AstraZeneca during the 1st quarter valued at $28,000.  Accurate Wealth Management LLC purchased a new stake in  AstraZeneca during the 4th quarter worth about $30,000.  Finally, Red Tortoise LLC bought a new position in  AstraZeneca in the 4th quarter worth about $30,000. 16.42% of the stock is owned by institutional investors.

Shares of AZN opened at $75.02 on Wednesday. AstraZeneca PLC has a 1-year low of $52.65 and a 1-year high of $75.83. The company has a market capitalization of $232.54 billion, a P/E ratio of 70.11, a P/E/G ratio of 1.52 and a beta of 0.52. The company has a debt-to-equity ratio of 0.62, a current ratio of 0.86 and a quick ratio of 0.68. The firm’s 50 day simple moving average is $67.38 and its 200 day simple moving average is $67.69.

AstraZeneca (NASDAQ:AZN – Get Rating) last posted its quarterly earnings data on Thursday, February 9th. The company reported $0.69 earnings per share for the quarter, beating the consensus estimate of $0.68 by $0.01. AstraZeneca had a net margin of 7.42% and a return on equity of 28.63%. The firm had revenue of $11.21 billion for the quarter, compared to analysts’ expectations of $11.40 billion.  Sell-side analysts forecast that  AstraZeneca PLC will post 3.6 earnings per share for the current fiscal year.

The company also recently declared a semi-annual dividend, which was paid on Monday, March 27th. Shareholders of record on Friday, February 24th were paid a dividend of $0.985 per share. The ex-dividend date  was Thursday, February 23rd. This represents a yield of 2%. This is a positive change from AstraZeneca’s previous semi-annual dividend of $0.47. AstraZeneca’s payout ratio is 180.38%.

AZN has been the topic of a number of recent analyst reports. BMO Capital Markets initiated coverage on shares of AstraZeneca in a report on Thursday, January 5th. They issued an “outperform” rating on the stock. Berenberg Bank increased their target price on shares of AstraZeneca from GBX 118 ($1.46) to GBX 126 ($1.56) in a research note on Wednesday, January 18th. StockNews.com assumed coverage on shares of AstraZeneca in a report on Thursday, March 16th. They issued a “strong-buy” rating for the company. Finally, Morgan Stanley raised shares of AstraZeneca from an “equal weight” rating to an “overweight” rating in a report on Tuesday, April 11th. One analyst  has rated the stock with a sell rating, three have assigned  a hold rating, four have given a buy rating and one  has given a strong buy rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $126.00.

AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.

Want to see what other hedge funds are holding AZN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AstraZeneca PLC (NASDAQ:AZN – Get Rating).

Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.